Compare Indonesia Energy Corporation Limited (INDO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs TG Therapeutics Inc — how do they compare? Indonesia Energy Corporation Limited trades at $2.77 (market cap $43.24M), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 188.7× Indonesia Energy Corporation Limited's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and TG Therapeutics Inc for 16 Days on average.
| INDO | TGTX | |
|---|---|---|
Market Cap | $43.24M | $8.16B |
Volume | 116,953 | 1,735,121 |
Sector | Energy | Health |
52-Week High | $6.74 | $59.06 |
52-Week Low | $2.49 | $26.94 |
Typical Hold Time | 24 Days | 16 Days |
Enterprise Value | $38.18M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.74, down 1.08% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $5.10 million on $2.01 million revenue in 2025, with negative profit margins and cash flow from operations. Recent news highlights progress on the K-29 well drilling and upcoming investor presentations.
Despite a 100% buy rating from 3 analysts, INDO faces significant financial challenges with persistent losses and negative cash flow. The stock's outlook hinges on successful production from new wells, but execution risks and weak fundamentals present substantial downside potential for investors.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
